<?xml version="1.0" encoding="utf-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
<channel>
                    <title>Clinical pharmacology</title>
            <link>https://medicalxpress.com/medications-news/</link>
            <language>en-us</language> 
            <description>Latest medical news and research in Clinical pharmacology</description>

                            <item>
                    <title>Possible new treatment for Wilson disease seeks to minimize effects on mitochondria using metformin</title>
                    <description>Wilson disease is a rare genetic condition in which the liver loses the ability to effectively remove copper, allowing it to accumulate in the body. This toxic buildup affects the liver, brain, eyes and kidneys and is particularly bad for mitochondria, the cell&#039;s all-important power plants.</description>
                    <link>https://medicalxpress.com/news/2026-11-treatment-wilson-disease-minimize-effects.html</link>
                    <category></category>
                    <pubDate>Thu, 19 Nov 2026 17:20:02 EST</pubDate>
                    <guid isPermaLink="false">news714324541</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/possible-new-treatment.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>One Health collaboration leads to potential targets against leishmaniasis, a parasitic disease</title>
                    <description>Leishmania parasites cause leishmaniasis. The disease is spread through the bite of an infected sand fly. While in the bloodstream, parasites invade host cells where they live and multiply.</description>
                    <link>https://medicalxpress.com/news/2026-11-health-collaboration-potential-leishmaniasis-parasitic.html</link>
                    <category></category>
                    <pubDate>Thu, 19 Nov 2026 16:40:01 EST</pubDate>
                    <guid isPermaLink="false">news714323761</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/one-health-collaborati.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Two new 16-week tuberculosis regimens advance in clinical trial</title>
                    <description>Tuberculosis remains one of the world&#039;s deadliest infectious diseases, causing more than 1 million deaths each year. The development of new therapeutic regimens remains slow, costly and complex, while treatment remains lengthy and patients face the burden of side effects. Accelerating the identification of safer, shorter and more effective treatment options is essential to achieving global TB elimination goals.</description>
                    <link>https://medicalxpress.com/news/2026-11-week-tuberculosis-regimens-advance-clinical.html</link>
                    <category></category>
                    <pubDate>Thu, 19 Nov 2026 13:40:05 EST</pubDate>
                    <guid isPermaLink="false">news714304446</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/laboratory-work-as-par.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Can a small DNA fix protect against Parkinson&#039;s disease?</title>
                    <description>In 2021, researchers at Oslo University Hospital discovered that by switching off a specific gene in the roundworm C. elegans, they could protect a particular type of nerve cell from age-related degeneration. These are the same types of nerve cells that are affected in patients with Parkinson&#039;s disease.</description>
                    <link>https://medicalxpress.com/news/2026-11-small-dna-parkinson-disease.html</link>
                    <category></category>
                    <pubDate>Thu, 19 Nov 2026 10:40:11 EST</pubDate>
                    <guid isPermaLink="false">news714292643</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/dna-fix.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Therapeutic antibody protects against all three pathogenic human coronaviruses</title>
                    <description>A therapeutic antibody (bispecific nanobody) developed by researchers at Georgia State University and collaborators neutralized all three highly pathogenic human coronaviruses (SARS-CoV, SARS-CoV-2 and MERS-CoV) and protected animals from viral infections, according to a study published in the journal ACS Nano.</description>
                    <link>https://medicalxpress.com/news/2026-11-therapeutic-antibody-pathogenic-human-coronaviruses.html</link>
                    <category></category>
                    <pubDate>Thu, 19 Nov 2026 09:40:08 EST</pubDate>
                    <guid isPermaLink="false">news714301741</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/therapeutic-antibody-p-1.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Experimental GLS-1 inhibitor demonstrates antitumor activity in advanced treatment-resistant ovarian cancer</title>
                    <description>Combining the experimental therapy IACS-6274 with targeted therapy bevacizumab and paclitaxel chemotherapy showed promising antitumor activity in a Phase I trial of patients with advanced platinum-resistant ovarian cancer, according to new results presented by researchers from The University of Texas MD Anderson Cancer Center.</description>
                    <link>https://medicalxpress.com/news/2026-11-experimental-gls-inhibitor-antitumor-advanced.html</link>
                    <category></category>
                    <pubDate>Thu, 19 Nov 2026 09:40:05 EST</pubDate>
                    <guid isPermaLink="false">news714292159</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/experimental-gls1-inhi.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Experimental antibody-drug conjugate shows promising initial activity in head and neck cancers</title>
                    <description>The investigational antibody-drug conjugate (ADC) micvotabart pelidotin (MICVO, PYX-201) demonstrated promising antitumor activity and a manageable safety profile in a Phase I trial presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics by researchers at The University of Texas MD Anderson Cancer Center.</description>
                    <link>https://medicalxpress.com/news/2026-11-experimental-antibody-drug-conjugate-neck.html</link>
                    <category></category>
                    <pubDate>Thu, 19 Nov 2026 08:30:04 EST</pubDate>
                    <guid isPermaLink="false">news714287921</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2025/patient-6.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Antibody-drug conjugate shows promising early results in Phase I trial in sarcoma patients</title>
                    <description>An antibody-drug conjugate, a type of drug that targets and enters cancer cells like a Trojan Horse, has shown promising early results across diverse types of soft tissue sarcoma in a Phase I trial. The findings were presented at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.</description>
                    <link>https://medicalxpress.com/news/2026-11-antibody-drug-conjugate-early-results.html</link>
                    <category></category>
                    <pubDate>Thu, 19 Nov 2026 06:39:42 EST</pubDate>
                    <guid isPermaLink="false">news714292751</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2020/6-patient.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Neurosteroid offers clues to brain changes linked to depression</title>
                    <description>UT Southwestern Medical Center researchers and colleagues, including two at UT Dallas, have found evidence that pregnenolone—a naturally occurring steroid hormone the body produces from cholesterol—may alter patterns of communication between key brain regions involved in depression and cognitive control.</description>
                    <link>https://medicalxpress.com/news/2026-11-neurosteroid-clues-brain-linked-depression.html</link>
                    <category></category>
                    <pubDate>Thu, 19 Nov 2026 05:20:09 EST</pubDate>
                    <guid isPermaLink="false">news714286581</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/neurosteroid-offers-cl.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>How research paved the way for progress in a rare form of ALS</title>
                    <description>An experimental ALS drug that grew out of basic and clinical research at Columbia University&#039;s Vagelos College of Physicians and Surgeons may soon become available for patients with a rare and aggressive form of the disease.</description>
                    <link>https://medicalxpress.com/news/2026-11-paved-rare-als.html</link>
                    <category></category>
                    <pubDate>Wed, 18 Nov 2026 19:00:06 EST</pubDate>
                    <guid isPermaLink="false">news714239161</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/neuron-1.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>No clear benefit from two drugs intended to increase spontaneous birth after induction in first-time moms</title>
                    <description>There is no clear evidence that hyoscine butylbromide or sodium bicarbonate improves spontaneous vaginal birth rates (without the assistance of forceps or vacuum) in first-time moms after induction of labor, finds a large Norwegian trial published by The BMJ. Although small benefits of either drug can&#039;t be entirely ruled out, the researchers say the findings do not support their routine use.</description>
                    <link>https://medicalxpress.com/news/2026-11-benefit-drugs-spontaneous-birth-induction.html</link>
                    <category></category>
                    <pubDate>Wed, 18 Nov 2026 18:30:06 EST</pubDate>
                    <guid isPermaLink="false">news714205999</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/woman-in-labor.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>CBD oil offers no behavioral benefit for youths with intellectual disability, new study finds</title>
                    <description>Cannabis contains two key compounds that act on the brain: cannabidiol (CBD) and tetrahydrocannabinol (THC). Although both interact with the body&#039;s endocannabinoid system, the outcomes of consuming them are poles apart. THC is the compound responsible for marijuana&#039;s intoxicating high and can sometimes trigger adverse effects, including psychosis. CBD, on the other hand, is associated with potential anxiety-relieving and anti-inflammatory effects. Despite limited evidence that it works, over the last decade, CBD-rich medical cannabis has gained popularity as a treatment for behavioral problems in children with autism spectrum disorder (ASD).</description>
                    <link>https://medicalxpress.com/news/2026-11-cbd-oil-behavioral-benefit-youths.html</link>
                    <category></category>
                    <pubDate>Wed, 18 Nov 2026 15:40:20 EST</pubDate>
                    <guid isPermaLink="false">news714235473</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/cbd-oil-offers-no-beha.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Novel compound eases paralysis and activates nerve repair pathways in multiple sclerosis mouse model</title>
                    <description>A new derivative of a natural compound reduced symptoms associated with multiple sclerosis and promoted the central nervous system&#039;s regenerative pathways in a mouse model, report researchers at the University of Illinois Urbana-Champaign and collaborators at Keio University and Chiba University in Japan.</description>
                    <link>https://medicalxpress.com/news/2026-11-compound-eases-paralysis-nerve-pathways.html</link>
                    <category></category>
                    <pubDate>Wed, 18 Nov 2026 15:00:04 EST</pubDate>
                    <guid isPermaLink="false">news714235082</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/novel-compound-improve.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>1 in 10 U.S. adults reported GLP-1 medication use July to August 2025</title>
                    <description>From July to August 2025, about one in 10 U.S. adults reported taking a glucagon-like peptide-1 receptor agonist (GLP-1 RA) medication during the past year, according to research published in Morbidity and Mortality Weekly Report.</description>
                    <link>https://medicalxpress.com/news/2026-11-adults-glp-medication-july-august.html</link>
                    <category></category>
                    <pubDate>Wed, 18 Nov 2026 12:00:10 EST</pubDate>
                    <guid isPermaLink="false">news714218769</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/glp-1-1.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Study explores potential antiviral treatment approach for long COVID</title>
                    <description>Researchers have reported encouraging results from a new feasibility study looking to find a potential treatment for long COVID.</description>
                    <link>https://medicalxpress.com/news/2026-11-explores-potential-antiviral-treatment-approach.html</link>
                    <category></category>
                    <pubDate>Wed, 18 Nov 2026 11:50:08 EST</pubDate>
                    <guid isPermaLink="false">news714218215</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/study-explores-potenti.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>New guidance addresses GLP-1 medication use and eating disorders</title>
                    <description>GLP-1 medications are widely used to treat type 2 diabetes and help some people manage their weight. These medications can reduce appetite and help people feel full sooner. Early research also suggests they may help reduce binge-eating episodes for some people.</description>
                    <link>https://medicalxpress.com/news/2026-11-guidance-glp-medication-disorders.html</link>
                    <category></category>
                    <pubDate>Wed, 18 Nov 2026 11:20:01 EST</pubDate>
                    <guid isPermaLink="false">news714218175</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2025/ozempic-4.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Inspired by &#039;Flowers for Algernon,&#039; experimental nose drops improve memory in mice</title>
                    <description>Researchers at the University of Sydney have developed experimental nose drops that enhance learning and memory in aged mice while also preventing memory loss in a mouse model of Alzheimer&#039;s disease. The treatment uses mRNA technology similar to that developed for use in COVID-19 vaccines.</description>
                    <link>https://medicalxpress.com/news/2026-11-algernon-experimental-nose-memory-mice.html</link>
                    <category></category>
                    <pubDate>Wed, 18 Nov 2026 05:00:01 EST</pubDate>
                    <guid isPermaLink="false">news714127081</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/experimental-nose-drop.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Chewable fish oil emulsion supplements may be better than soft-gel capsules</title>
                    <description>In a crossover clinical trial published in the European Journal of Lipid Science and Technology, investigators found that a chewable fish oil emulsion supplement may provide higher circulating levels of omega-3 fatty acids compared with a soft gel.</description>
                    <link>https://medicalxpress.com/news/2026-11-chewable-fish-oil-emulsion-supplements.html</link>
                    <category></category>
                    <pubDate>Wed, 18 Nov 2026 03:10:04 EST</pubDate>
                    <guid isPermaLink="false">news714056605</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2019/fishoil.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Psilocybin may improve a difficult-to-treat symptom of depression, study finds</title>
                    <description>New research from the University of Colorado Anschutz suggests that psilocybin may help improve anhedonia, the loss of interest or ability to experience pleasure, in people with treatment-resistant depression. In a clinical trial, researchers found significant improvement in this difficult-to-treat symptom eight weeks after treatment, offering new insight into psilocybin&#039;s potential role in depression care.</description>
                    <link>https://medicalxpress.com/news/2026-11-psilocybin-difficult-symptom-depression.html</link>
                    <category></category>
                    <pubDate>Tue, 17 Nov 2026 22:00:01 EST</pubDate>
                    <guid isPermaLink="false">news714143121</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2024/psilocybin.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>FDA approves first factor XIa inhibitor for secondary stroke prevention</title>
                    <description>The U.S. Food and Drug Administration has approved Sunharbo (asundexian) 50 mg tablets, in combination with antiplatelet therapy, to reduce the risk for stroke in adults following a recent mild-to-moderate noncardioembolic ischemic stroke or a high-risk transient ischemic attack (TIA).</description>
                    <link>https://medicalxpress.com/news/2026-11-fda-factor-xia-inhibitor-secondary.html</link>
                    <category></category>
                    <pubDate>Tue, 17 Nov 2026 21:20:06 EST</pubDate>
                    <guid isPermaLink="false">news714142774</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/stroke-risk.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>GLP-1 weight-loss drugs linked to inadequate intake of key nutrients in some people</title>
                    <description>Drugs taken to suppress appetite, such as Wegovy and Mounjaro, are associated with inadequate intakes of key nutrients and energy in some people, finds a small exploratory study published in the journal BMJ Nutrition Prevention &amp; Health.</description>
                    <link>https://medicalxpress.com/news/2026-11-glp-weight-loss-drugs-linked.html</link>
                    <category></category>
                    <pubDate>Tue, 17 Nov 2026 18:30:06 EST</pubDate>
                    <guid isPermaLink="false">news714054841</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/person-taking-suppleme.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>First evidence from a Chinese population supports review of long-term blood monitoring for local clozapine use</title>
                    <description>An international research team led by the Department of Psychiatry, School of Clinical Medicine, LKS Faculty of Medicine of the University of Hong Kong (HKUMed), has completed a long-term population-based research study to improve care for people with treatment-resistant schizophrenia (TRS), the most severe form of this mental health condition. The findings reinforce the importance of timely access to clozapine and provide the first large-scale evidence from a Chinese population to support a review of Hong Kong&#039;s long-term blood monitoring requirements.</description>
                    <link>https://medicalxpress.com/news/2026-11-evidence-chinese-population-term-blood.html</link>
                    <category></category>
                    <pubDate>Tue, 17 Nov 2026 18:20:16 EST</pubDate>
                    <guid isPermaLink="false">news714142458</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/hkumed-research-provid.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>For military veterans with PTSD and alcohol use disorder, MDMA-assisted therapy may be safe, effective</title>
                    <description>The first study of a program that uses the drug MDMA to treat post-traumatic stress disorder (PTSD) plus alcohol use disorder in military veterans has concluded with promising results.</description>
                    <link>https://medicalxpress.com/news/2026-11-military-veterans-ptsd-alcohol-disorder.html</link>
                    <category></category>
                    <pubDate>Tue, 17 Nov 2026 17:20:09 EST</pubDate>
                    <guid isPermaLink="false">news714138621</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/veteran-therapy-1.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>First successful human challenge model for dengue serotype 4 could speed vaccine and drug testing</title>
                    <description>Researchers at the University of Maryland School of Medicine (UMSOM) and the Institute of Human Virology (IHV) have developed the first successful human challenge model for dengue serotype 4, a major advance that could speed the development of new drugs and vaccines against a strain of the dengue virus that remains difficult to study.</description>
                    <link>https://medicalxpress.com/news/2026-11-successful-human-dengue-serotype-vaccine.html</link>
                    <category></category>
                    <pubDate>Tue, 17 Nov 2026 16:20:28 EST</pubDate>
                    <guid isPermaLink="false">news714152402</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2017/dengue.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Five things that shape body weight—by an obesity expert</title>
                    <description>What you eat when you&#039;re tired and hungry might come down to what&#039;s open on the way home and what you can afford. Both appetite and access to food shape decisions that can look, from the outside, like simple matters of choice.</description>
                    <link>https://medicalxpress.com/news/2026-11-body-weight-obesity-expert.html</link>
                    <category></category>
                    <pubDate>Tue, 17 Nov 2026 14:30:01 EST</pubDate>
                    <guid isPermaLink="false">news714132274</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/snacking.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Increasing methadone doses associated with improved quality of life</title>
                    <description>The introduction of fentanyl, a potent synthetic opioid, into the U.S. drug supply has remade the landscape for health and recovery. This includes changing norms around the use of methadone, a common treatment option for opioid use disorder.</description>
                    <link>https://medicalxpress.com/news/2026-11-methadone-doses-quality-life.html</link>
                    <category></category>
                    <pubDate>Tue, 17 Nov 2026 10:20:05 EST</pubDate>
                    <guid isPermaLink="false">news714125421</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2025/methadone.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>New SARS-CoV-2 variant PJ.2.1: Vaccine antibodies provide protection</title>
                    <description>Germany&#039;s COVID-19 traffic light is red, and the number of infections is high. But how well is the population protected against the virus variants currently circulating? The new SARS-CoV-2 variant PJ.2.1 has been spreading since May and has long since reached Europe. It traces back to an older viral lineage that has since largely disappeared from the infection landscape. However, the virus likely persisted in a person with a long-term infection and underwent significant changes through numerous mutations.</description>
                    <link>https://medicalxpress.com/news/2026-11-sars-cov-variant-pj21-vaccine.html</link>
                    <category></category>
                    <pubDate>Tue, 17 Nov 2026 09:00:06 EST</pubDate>
                    <guid isPermaLink="false">news714120561</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/new-sars-cov-2-variant.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Tirzepatide moves more than half of treated teens below obesity threshold, new clinical trial reports</title>
                    <description>Tirzepatide (Zepbound) is a once-weekly injectable medication that hits two targets at once. This dual-action drug mimics the effects of two natural gut hormones in the body—glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Working together, these hormones keep blood sugar in check, slow the movement of food through the gut and signal the brain about fullness, which helps manage appetite and food intake.</description>
                    <link>https://medicalxpress.com/news/2026-11-tirzepatide-teens-obesity-threshold-clinical.html</link>
                    <category></category>
                    <pubDate>Tue, 17 Nov 2026 08:30:04 EST</pubDate>
                    <guid isPermaLink="false">news714126561</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/tirzepatide-moved-more.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Researchers find potential way to protect the brain from HIV and opioid damage</title>
                    <description>People living with HIV continue to struggle with memory loss, difficulty concentrating and poor decision-making, even as antiretroviral treatments have dramatically improved life expectancy. For patients who also use opioids—which may be prescribed to manage the chronic pain that can accompany HIV—these cognitive problems can be even worse. Until now, scientists haven&#039;t understood exactly why.</description>
                    <link>https://medicalxpress.com/news/2026-11-potential-brain-hiv-opioid.html</link>
                    <category></category>
                    <pubDate>Mon, 16 Nov 2026 15:40:06 EST</pubDate>
                    <guid isPermaLink="false">news714061502</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2019/8-brain.jpg" width="90" height="90" />
                                    </item>
                            <item>
                    <title>Astaxanthin supplements: What the science says about skin, exercise and your brain</title>
                    <description>Smoother skin, sharper eyesight, better memory, stronger joints, improved athletic performance and even protection against aging—astaxanthin is marketed as a supplement with an extraordinary range of health benefits. But how much of this promise is backed by evidence in people?</description>
                    <link>https://medicalxpress.com/news/2026-11-astaxanthin-supplements-science-skin-brain.html</link>
                    <category></category>
                    <pubDate>Mon, 16 Nov 2026 13:40:26 EST</pubDate>
                    <guid isPermaLink="false">news714052458</guid>
                                            <media:thumbnail url="https://scx1.b-cdn.net/csz/news/tmb/2026/supplement-capsule.jpg" width="90" height="90" />
                                    </item>
                    </channel>
</rss>
